2014—2016年南京地区34家医院抗痛风药物的使用情况分析

目的 对南京地区34家医院抗痛风药物的应用情况进行回顾性分析，为抗痛风药物的开发、生产、营销及合理利用提供参考和依据。方法 对2014—2016年南京地区34家医院抗痛风药物的用量、销售金额、用药频度（DDDs）、日均药费（DDC）及药品排序比（B/A）等进行统计和分析。结果 南京地区抗痛风药物的销售金额和DDDs都逐年增长，苯溴马隆连续两年占主导地位，增长率最快的药物均是减少尿酸合成的药物非布司他，4种药物的排序无明显变化。DDC最大的为非布司他，秋水仙碱的DDC最小。B/A比值接近1.00的品种别嘌醇和苯溴马隆。结论 南京地区34家医院临床用药时基本能遵循指南要求选择合适的抗痛风药物，但供选择的药物品种少，有待开发新的药物。

Analysis on utilization of anti-gout drugs in 34 hospitals from Nanjing area from 2014 to 2016

Objective To evaluate the clinical application of anti-gout drugs in 34 hospitals from Nanjing area, to provide the basis methods for the production, marketing, and clinical application of anti-gout drugs. Methods The utilization information of anti-gout drugs in 34 hospitals from Nanjing area from 2014 to 2016 was extracted, and the consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results Consumption sum and DDDs of anti-gout drugs were both increased per year from 2014 to 2016. And benzbromarone occupied most marketing by two years. Among all the anti-gout drugs, febuxostat was the drugs with most obviously increased rate. The sequence of anti-gout drugs was stable. DDC of febuxostat was the highest, while DDC of colchicines was the lowest. Conclusion The application of anti-gout drugs in 34 hospitals from Nanjing area can follow the medication guide. But the varieties of anti-gout drugs is not abundant, it needs to develop the new drugs.